Zacks Investment Research downgraded Paratek Pharmaceuticals Inc (NASDAQ:PRTK) to Sell in a report released today.
- Updated: October 8, 2016
Zacks Investment Research has downgraded Paratek Pharmaceuticals Inc (NASDAQ:PRTK) to Sell in a report released on 10/06/2016.
Previously on 5/13/2016, Robert W. Baird released a statement about Paratek Pharmaceuticals Inc (NASDAQ:PRTK) increased the target price from $0.00 to $30.00. At the time, this indicated a possible upside of 1.37%.
Just yesterday Paratek Pharmaceuticals Inc (NASDAQ:PRTK) traded -1.32% lower at $13.99. Paratek Pharmaceuticals Inc’s 50-day moving average is $13.46 and its 200-day moving average is $14.04. The last stock price is down -4.32% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 80,785 shares of PRTK traded hands, down from an average trading volume of 141,558
Recent Performance Chart
Paratek Pharmaceuticals Inc has 52 week low of $12.05 and a 52 week high of $24.00 and has a market capitalization of $0.
In addition to Zacks Investment Research reporting its stock price target, a total of 1 brokerage has issued a research note on the company. The average stock price target is $3.80 with 4 firms rating the stock a strong buy, 3 firms rating the stock a buy, 0 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 brokers rating the stock a sell.
General Information About Paratek Pharmaceuticals Inc (NASDAQ:PRTK)
Paratek Pharmaceuticals, Inc. (Paratek), formerly Transcept Pharmaceuticals, Inc. is a pharmaceutical company focused on the development and commercialization of antibacterial therapeutics based upon tetracycline chemistry. Paratek's antibacterial product candidates are omadacycline and sarecycline. Omadacycline is a broad-spectrum antibiotic for use as an empiric monotherapy for community-acquired bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP) and urinary tract infections (UTI). The Company's sarecycline is a Phase III antibacterial product candidate and was previously known as WC3035. Sarecycline is designed for use in the treatment of acne and rosacea. The Company's other product candidates are tetracycline-derived, molecular entities and are designed to utilize the recognized immune-modulation, anti-inflammatory and other beneficial properties of the tetracycline class.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.